Dongchao Xu

Dongchao Xu

Auto-generated profile, based on publicly available information

Dongchao Xu

Department of Gastroenterology, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou 310000, China; Hangzhou Institute of Digestive Diseases, Hangzhou 310000, China; Key Laboratory of Integrated Traditional Chinese and Western Medicine for Biliary and Pancreatic Diseases of Zhejiang Province, Hangzhou 310000, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2024 in International Immunopharmacology
Verified
Journal Article
Closed access
DXDongchao Xu
Dongchao Xu
HWHao Wu
Hao Wu
MTMengyao Tian
Mengyao Tian
QLQiang Liu
Qiang Liu
YZYuanling Zhu
Yuanling Zhu
HSHong-Zhang Shen
Hong-Zhang Shen

17 September 2023 in Biochemical Pharmacology
Verified
Journal Article
Closed access
DXDongchao Xu
Dongchao Xu
ALAjuan Liu
Ajuan Liu
QLQiang Liu
Qiang Liu
HZHongchen Zhang
Hongchen Zhang
MTMengyao Tian
Mengyao Tian
HSHong-Zhang Shen
Hong-Zhang Shen

4 August 2022 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
DXDongchao Xu
Dongchao Xu
MTMengyao Tian
Mengyao Tian
WCWangyang Chen
Wangyang Chen
YBYing Bian
Ying Bian
XXXiaofeng Xia
Xiaofeng Xia
HSHong-Zhang Shen
Hong-Zhang Shen
Linderalactone is one of the main extracts of Linderae Radix, which is widely used in traditional Chinese medicine. There have been few studies on the antitumor effect of linderalactone in the past. In this study, we explored the anti-pancreatic cancer activity of linderalactone in vitro and in vivo. The results showed that linderalactone inhibited the proliferation of pancreatic cancer cells in a time- and dose-dependent manner. Cell migration and invasion were significantly inhibited by linderalactone. The cell cycle was arrested in the G2/M phase, and the expression levels of cell cycle-associated proteins changed significantly with linderalactone treatment. In addition, linderalactone induced cell apoptosis and altered the expression of apoptotic markers, such as caspase 3 and PARP1. Mechanistically, linderalactone suppressed the PI3K/AKT signaling pathway by downregulating the phosphorylation of PI3K and AKT. The xenograft study results were consistent with the in vitro results, and there was no obvious chemical toxicity. Thus, our research demonstrated that linderalactone exhibits antitumor activity against pancreatic cancer and may be developed as a potential anti-pancreatic cancer agent in the future.